The Efficacy and Safety of On-demand Tramadol and Paroxetine Use in Treatment of Life Long Premature Ejaculation: A Randomized Double-blind Placebo-controlled Clinical Trial.
Premature ejaculation (PE) is the most common sexual dysfunction in men (1-2) and may affect many aspects of the life of men, including the loss of confidence, loss of relationships, feelings of anxiety, anger and depression (3).
Its prevalence has been reported about 2 to 23% in some studies (4-5). This wide range of prevalence can be caused by different definitions of PE in studies or reflect the differences in diverse populations (6). It seems that all men have experienced PE during their sexual life.
According to the International Society for Sexual Medicine (ISSM), lifelong PE is defined as "a male sexual dysfunction characterized by ejaculation which always or nearly always occurs before or within approximately 1 min of vaginal penetration; the inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration, and/or the avoidance of sexual intimacy" (7).
PE is divided into two categories: primary (lifelong) and secondary or acquired (6, 8). Lifelong PE begins from the onset of sexual maturity and remains as a problem during life. In lifelong PE, ejaculation occurs in less than 1-2 min after vaginal penetrating and even before that. Acquired PE develops after an interval of normal sexual function (9). The prevalence of lifelong PE is estimated to be 2-5% and it is 20-30% in acquired PE (10, 11).
Currently, available treatments for PE include selective serotonine re-uptake inhibitors (SSRIs), 1-adrenoreceptor antagonists, the analgesic opioid receptor agonist, antidepressants, local anesthetic agents, phosphodiesterase type 5 inhibitors, etc. (6, 8, 12, 13) and each of them has shown varying degrees of effectiveness and side effects (8) and none of them is generally approved for the treatment of PE.
The efficacy of off-label SSRIs in delaying ejaculation with the low side effect makes them the first choice of treatment in PE either on a daily or an on-demand basis (14-16). Paroxetine causes strongest delay in ejaculation compared with other SSRIs. (16) It can be used either on-demand or daily (8, 13, 16). However, the results of the SSRIs' treatment are not universally successful (17, 18).
Also, the safety and efficacy of tramadol as an analgesic opioid receptor for treatment of lifelong PE has been shown in some recent studies (14, 19-21).
In the present study, the purpose was to compare the safety and efficacy of tramadol, paroxetine and placebo in delaying the intravaginal ejaculation latency time (IELT), improving satisfaction with sexual intercourse and control over ejaculation and decrease ejaculation-related distress and interpersonal difficulty.
Between July 2013 and September 2014, a total of 150 healthy men with complaining of lifelong PE who referred to the urology clinic of our university hospital or three other private urology clinics in Rasht enrolled in this double-blind clinical trial.
All men were between 18 to 55 years old, married and had a stable relationship for at least 6 months. PE was defined as uncontrolled ejaculation that occurred before or within 1 min of vaginal intercourse. All patients provided a detailed medical and sexual history and physical examination was done for all of them. Exclusion criteria included patients with secondary PE, other sexual dysfunction including erectile dysfunction (ED) according to the international index of erectile function (IIEF), history of a major psychiatric disorder, and endocrine disease (diabetes, liver disease, ...), prostatitis, physical illness or urogenital infection, history of addictive drugs or alcohol abuse, current use of paroxetine or tramadol and sensitivity to this kind of drugs.
An informed consent was obtained from all participants. The study was approved by the local ethics committee of Guilan University of Medical Sciences. It was registered online at Iranian Registry of Clinical Trials (http://www.irct.ir//:IRCT201008304582N2).
IELT and premature ejaculation profile (PEP) questionnaire were used to assess PE. The pre-treatment IELT was measured by using a partnerheld stop watch during a 3 week baseline period in which patients were asked to experience sexual intercourse at least 3 times. After this initial 3 week screening period, the patients were randomly divided in 3 groups. One group received 50 mg tramadol. The other group received 20 mg paroxetine and the last group received the placebo. All three pills were identical in appearance and were administered on-demand (2-3 hr before the planned intercourse). All patients and investigators were blinded regarding the type of treatment received. Patients were asked to have intercourse at least 6 times and record each IELT throughout these 12 weeks of treatment. Patients were also requested not to use condoms or topical penile anesthetic creams or sprays. At the end of the 12th week, the last 3 IELTs -during the last 3 weeks-for each person were recorded.
The PEP is a validated self-reported questionnaire which contains four items including sexual satisfaction, control over ejaculation, distress and interpersonal difficulty. Each item has 5 possible response options. Each measure regarding ejaculation is scored on a 5 point scale. The PEP questionnaire was filled before and after treatment for all patients.
Statistical analysis: According to the normality of data (by Ks test), the IELT between the three groups was compared by Kruskal--Wallis test. The Wilcoxon Rank Test and paired T-test were used for comparing the IELT and PEP scores before and after treatment. The chi-square test was used for comparing the complications between the three groups. A p-value of <0.05 was considered statistically significant.
A total of 150 patients (range of age, 21-53) were enrolled in this study and randomly divided into 3 groups. Of all the patients, only 126 (84%) cases completed the study period. In the midst of the study, 7(7/4%) patients discontinued due to adverse effects as well as 17 (3/11%) patients (1 case in the paroxetine group and 16 cases in the placebo group) due to the ineffectiveness of treatment. Consequently, the statistical analysis was performed for 126 patients at the end of study.
The mean age of the patients in tramadol group was 36.38[+ or -]7.92 years; the mean age of the patients in paroxetine group was 35.70[+ or -]7.89 years, and the mean age of the patients in placebo group was 36.60[+ or -]6.91 years. The mean age of the patients was similar between the 3 groups (p=0.575).
There was no statistical difference between the groups in terms of baseline IELTs (p=0.368) and PEP scores (p=0.349) (Table 1 and 3).
Significant increase of mean IELT after 12 weeks was observed in all groups (p<0.001). Also, there was statistically significant difference between groups in the improvement of IELT. The increase in the tramadol group (136.98[+ or -]77.27) was significantly greater than the paroxetine (91.17[+ or -]73.22) and placebo (77.97[+ or -]54.96) group (p<0.0001).
A comparison of the increase in the IELTs of three groups after treatment has demonstrated a statistically significant difference (p<0.0001). ELTs changes are shown in table 1.
According to table 2, IELT changes in tramadol group were statistically significant compared to both paroxetine and placebo groups (p<0.0001). But no significant difference was found in paroxetine group versus placebo (p=0.186).
The PEP scores increased from 8.78[+ or -]2.74 to 13.31[+ or -] 3.47 in tramadol group, from 9.38[+ or -]2.55 to 11.30[+ or -] 3.86 in the paroxetine group and from 9.60[+ or -]3.01 to 9.97[+ or -]3.42 in the placebo group (Table 3).
Changes from baseline were significantly greater with tramadol (p<0.0001). All PEP measures improved significantly with tramadol (p<0.0001) and paroxetine groups (p<0.05). Despite the improvement of PEP scores in the placebo group, changes in any of the items were not significant (p>0.05) (Table 4).
Table 5 shows PEP score changes in tramadol group which was significantly greater than both paroxetine and placebo groups (p<0.0001). But the changes in paroxetine group was not significant compared to placebo (p=0.16).
No serious adverse effect was observed in the groups. Two patients (4%) in tramadol group reported mild lethargy and drowsiness, 3 patients (6.1%) in paroxetine group had mild fatigue and drowsiness, and 2 patients (5.9%) in placebo group reported mild drowsiness. There was some report about the mild nausea and headache in tramadol group that were tolerated by the patients. Upon comparison of the groups' reported side effects, there was no significant difference between groups (p=0.879).
Unlike erectile dysfunction (ED), which further affects the older men, PE is the same as occurs in all ages (5, 12). It should be mentioned that PE is not associated with any physiological deficiency and the physiological events of PE are generally normal (22, 23). Because PE has negative effects on quality of sexual life by affecting the satisfaction of the couple, it can be very bothersome. Therefore, the necessity for new treatments for PE is still remaining (23).
The aim of this study was to focus on ejaculation delay and sexual function improvement after on-demand treatment by the measure of IELT and PEP scores together.
In most previous studies, treatment with paroxetine is administered on a daily basis, but in this study, like some others (8, 12, 24) an on-demand (2-3 hr before intercourse) oral treatment for lifelong PE was examined.
In the current study, it was shown that the overall efficacy of tramadol is stronger than paroxetine in ejaculation delay during on-demand treatment.
The action of tramadol as a central synthetic opioid analgesic that involves both m-opioid receptor binding and norepinephrine and serotonin reuptake inhibition makes it unique compared to other drugs of the group (14, 23, 25) and because of its acceptable safety can be prescribed for many years (14, 25).
A meta-analysis by Wu et al. (12) showed no difference between tramadol and paroxetine in terms of mean IELT changes (p<0.05). This meta-analysis that has been conducted in various populations concluded that tramadol is a safe and effective treatment for PE.
A successful therapeutic effect of on-demand tramadol in initial increase of the IELTS after 6 weeks compared with the baseline level was reported by Safarinejad and Hosseini (2006) and Salem et al. (2008) (19, 20). A similar finding was reported in 2012 in a study conducted by Kaynar et al. (14). After 8 weeks of treatment, the mean IELT in tramadol group increased significantly compared to the placebo group. In a crossover study by Alghobary et al. (26), the use of daily paroxetine and on-demand tramadol has been evaluated. The mean IELT after 6 weeks significantly increased in both groups, but after 12 weeks, the mean IELT in tramadol group declined while it increased again in paroxetine group compared to sixth weeks. They concluded that the use of daily paroxetine is more effective than tramadol in the treatment of lifelong PE, and tramadol cannot be recommended as a long term treatment.
Bar-Or et al. (21) in a 12-week study compared the therapeutic effects of tramadol with 2 different doses (62 and 89 mg) with placebo. The mean IELT increased in all 3 groups, but the increase in the tramadol group (4.2 fold in tramadol 62 mg and 2.5 fold in tramadol 89 mg) was significantly higher than placebo (6.1 fold) (p<0.001).
In our study, the mean IELT was significantly increased in all groups (p<0.0001). Patients in tramadol group had significantly higher IELT than the other 2 groups (p<0.0001). But changes in mean IELT in paroxetine group was not significant compared to placebo group (p=0.189).
In the present study, efficacy of the treatment was evaluated not only by IELT, but also by measurement of the satisfaction with sexual intercourse, control over ejaculation, personal distress and interpersonal difficulty. Changes in these variables more appropriately indicate the effects of the treatment in men with PE.
Based on Ozcan et al.'s (13) findings, treatment with paroxetine significantly improves the all 4 items of PEP questionnaire compared to the baseline (p<0.001). In another study, significant improvement was observed in all 4 items of PEP questionnaire at 62 and 89 mg of tramadol in treatment groups compared to placebo (p<0.05) (21).
In the present study, the mean PEP score increased in all 3 groups. The increase in PEP caused by tramadol was statistically significant compared with the other 2 groups (p<0.0001). The assessment of questionnaire showed that changes in all 4 items have been improved in all 3 groups except the item "concern" in tramadol group which increased significantly. However, these changes were statistically significant only in tramadol and paroxetine group (p<0.0001).
There were no serious adverse effects in groups (p=0.879). The most common side effects were mild lethargy, fatigue, and drowsiness in 3 groups.
Drowsiness is reported in many studies as a major adverse effect for paroxetine and tramadol (14, 24, 27). Also, there were some reports of gastrointestinal distress (26, 27). But the severity level of these side effects was often low.
The low effectiveness of paroxetine compared with other studies may be due to the on-demand usage of this agent in our study, as previous researches have shown that chronic daily treatment with SSRI agents is effective in delaying ejaculation (12, 28).
One of the most important limitations of this study was the large number of patients in placebo group who discontinued the study. A power calculation estimated 50 subjects for each arm to show significance but since our data showed significance with this sample size, the result can be acceptable.
Our findings indicated that 50 mg on-demand tramadol is more effective than on-demand paroxetine 20 mg as a long-term treatment of lifelong PE. So, tramadol is expected to be an alternative for the treatment of primary PE. Our study also showed that the use of on-demand paroxetine has no noticeable effect in comparison to placebo. However, further prospective studies with larger sample sizes are needed to conclusively prove these results.
This study was supported by Urology Research Center, Guilan University of Medical Sciences. And also, it is adapted from the specialty thesis of Reza Motiee.
Conflict of Interest
Authors declare they have no conflict of interest for this manuscript and do not have any financial interest.
(1.) Montorsi F. Prevalence of premature ejaculation: a global and regional perspective. J Sex Med. 2005;2 Suppl 2:96-102.
(2.) Raisi F, Farnia V, Ghanbarian N, Ghafuri Z. Effects of herbal vigRX on premature ejaculation: a randomized, double-blind study. Iran J Psychiatry. 2010;5 (1):4-6.
(3.) Symonds T, Roblin D, Hart K, Althof S. How does premature ejaculation impact a man s life? J Sex Marital Ther. 2003;29(5):361-70.
(4.) Serefoglu EC, Yaman O, Cayan S, Asci R, Orhan I, Usta MF, et al. Prevalence of the complaint of ejaculating prematurely and the four premature ejaculation syndromes: results from the Turkish society of andrology sexual health survey. J Sex Med. 2011;8 (2):540-8.
(5.) Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The premature ejaculation prevalence and attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol. 2007;51(3):816-24.
(6.) Mohee A, Eardley I. Medical therapy for premature ejaculation. Ther Adv Urol. 2011;3(5):211-22.
(7.) McMahon CG, Althof S, Waldinger MD, Porst H, Dean J, Sharlip I, et al. An evidence-based definition of lifelong premature ejaculation: report of the international society for sexual medicine ad hoc committee for the definition of premature ejaculation. BJU Int. 2008;102(3):338-50.
(8.) Gameel TA, Tawfik AM, Abou-Farha MO, Bastawisy MG, El-Bendary MA, El-Gamasy Ael-N. On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab J Urol. 2013;11(4):392-7.
(9.) Cooper AJ, Cernovsky ZZ, Colussi K. Some clinical and psychometric characteistics of primary and secondary premature ejaculations. J Sex Marital Ther. 1993;19(4):276-88.
(10.) Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, et al. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the global study of sexual attitudes and behaviores. Int J Impot Res. 2005; 17(1):39-57.
(11.) Patrick DL, Althof SE, Pryor JL, Rosen R, Rowland DL, Ho KF, et al. Premature ejaculation: an observational study of men and their partners. J Sex Med. 2005;2(3):358-67.
(12.) Wu T, Yue X, Duan X, Luo D, Cheng Y, Tian Y, et al. Efficacy and safety of tramadol for premature ejaculation: a systematic review and meta-analysis. Urology. 2012;80(3):618-24.
(13.) Ozcan L, Polat EC, Otunctemur A, Ozbek E. Duloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation. Int Urol Nephrol. 2015;47(2):283-7.
(14.) Kaynar M, Kilic O, Yurdakul T. On-demand tramadol hydrochloride use in premature ejaculation treatment. Urology. 2012;79(1):145-9.
(15.) Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two doubleblind, randomised controlled trials. Lancet. 2006; 368(9539):929-37.
(16.) Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998; 18(4):274-81.
(17.) Roblin D. Premature ejaculation: diagnosis and pharmacotherapy. Int J Pharm Med. 2000;14(6): 313-8.
(18.) Safarinejad MR. Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study. J Clin Psychopharmacol. 2008;28(1):39-44.
(19.) Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol. 2006; 26(1):27-31.
(20.) Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA. Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med. 2008;5(1):188-93.
(21.) Bar-Or D, Salottolo KM, Orlando A, Winkler JV; Tramadol ODT Study Group. A randomized doubleblind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes. Eur Urol. 2012;61(4):736-43.
(22.) Giuliano F, Clement P. Serotonin and premature ejaculation: from physiology to patient management. Eur Urol. 2006;50(3):454-66.
(23.) Giuliano FA. Tramadol for the treatment of premature ejaculation. Eur Urol. 2012;61(4):744-5.
(24.) Waldinger MD, Zwinderman AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double blind fixed-dose study with stopwatch assessment. Eur Urol. 2004;46(4):510-6.
(25.) Marcou TA, Marque S, Mazoit JX, Benhamou D. The median effective dose of tramadol and morphine for postoperative patients: a study of interactions. Anesth Analg. 2005;100(2):469-74.
(26.) Alghobary M, El-Bayoumy Y, Mostafa Y, Mahmoud el-HM, Amr M. Evaluation of tramadol on demand vs. daily paroxetine as a long-term treatment of lifelong premature ejaculation. J Sex Med. 2010;7(8):2860-7.
(27.) Eid MA, Ahmed HH, Ismail NN, Shehaat SY. Comparative study between tramadol (50 mg) on demand and paroxetine HCl (20 mg) on demand in the treatment of premature ejaculation. Hum J Androl. 2011;1(2):69-73.
(28.) Powell JA, Wyllie MG. "Up and coming" treatments for premature ejaculation: progress towards an approved therapy. Int J Impot Res. 2009;21(2): 107-15.
Ali Hamidi-Madani, Reza Motiee (*), Gholamreza Mokhtari, Hamidreza Nasseh, Samaneh Esmaeili, Ehsan Kazemnezhad
- Urology Research Center, School of Medicine, Razi hospital, Guilan University of Medical Sciences, Rasht, Iran
(*) Corresponding Author: Reza Motiee, Urology Research Center, Razi Hospital, Sardar Jangal St., Rasht, Iran E-mail: email@example.com
Received: Sept. 5, 2017
Accepted: Nov. 26, 2017
Table 1. Variations of intravaginal ejaculatory latency time (IELT) in different groups Characteristics Tramadol Paroxetine Baseline IELT 42.42[+ or -]17.20 43.20[+ or -]18.20 Treatment IELT 136.98[+ or -]77.27 91.17[+ or -]73.22 P-value 0.0001 0.0001 IELT increase (variation) 94.17[+ or -]73.97 48.02[+ or -]68.13 Characteristics Placebo p-value (*) Baseline IELT 47.71[+ or -]14.37 0.368 Treatment IELT 77.97[+ or -]54.96 0.0001 P-value 0.001 IELT increase (variation) 30.47[+ or -]53.32 0.0001 Table 2. Change in male intravaginal ejaculation latency time in different groups First group Second group Mean difference SE p-value paroxetine 46.14 13.85 0.0001 Diff-IELT Tramadol placebo 63.70 15.32 0.0001 paroxetine placebo 17.55 15.45 0.189 95% Confidence interval Lower Bound Upper Bound Diff-IELT 13.29 79.00 27.36 100.04 -19.10 54.21 Table 3. Change in male premature ejaculation profile score in different groups Premature Ejaculation Profile Questions Tramadol Baseline PEP scores % (n) 8.78[+ or -]2.74 Satisfaction with sexual intercourse (*) Control over ejaculation (*) 94 (47) Ejaculation-related interpersonal 88 (44) Difficulty (**) 22 (11) Ejaculation-related distress (**) 52 (26) Treatment PEP scores % (n) 13.31[+ or -]3.47 Satisfaction with sexual intercourse (*) Control over ejaculation (*) 41.7 (20) Ejaculation-related interpersonal 43.8 (21) Difficulty (**) 8.4 (4) Ejaculation-related distress (**) 23 (11) Diff-PEP 4.67[+ or -]4.08 Premature Ejaculation Profile Questions Paroxetine Baseline PEP scores % (n) 9.38[+ or -]2.55 Satisfaction with sexual intercourse (*) Control over ejaculation (*) 94 (47) Ejaculation-related interpersonal 80 (44) Difficulty (**) 18 (9) Ejaculation-related distress (**) 66 (33) Treatment PEP scores % (n) 11.30[+ or -]3.86 Satisfaction with sexual intercourse (*) Control over ejaculation (*) 94 (47) Ejaculation-related interpersonal 88 (44) Difficulty (**) 22 (11) Ejaculation-related distress (**) 52 (26) Diff-PEP 1.98[+ or -]3.38 Premature Ejaculation Profile Questions Placebo p-value Baseline PEP scores % (n) 9.60[+ or -]3.01 0.349 Satisfaction with sexual intercourse (*) Control over ejaculation (*) 78 (39) Ejaculation-related interpersonal 62 (31) Difficulty (**) 26 (13) Ejaculation-related distress (**) 50 (25) Treatment PEP scores % (n) 9.97[+ or -]3.42 0.0001 Satisfaction with sexual intercourse (*) Control over ejaculation (*) 94 (47) Ejaculation-related interpersonal 88 (44) Difficulty (**) 22 (11) Ejaculation-related distress (**) 52 (26) Diff-PEP 0.50[+ or -]2.64 0.0001 (*) Very poor or poor; (**) Extreme or quite a bit Table 4. Changes in PEP questionnaire's items before and after treatment in different groups Premature Ejaculation Profile Questions Tramadol Paroxetine Placebo Satisfaction with sexual intercourse (Z) -5.31 -3.55 -1.10 p-value 0.0001 0.0001 0.270 Control over ejaculation (Z) -5.39 -2.22 -0.09 p-value 0.0001 0.026 0.923 Ejaculation-related interpersonal difficulty (Z) -4.001 -2.34 -1.90 p-value 0.0001 0.019 0.057 Ejaculation-related distress (Z) -3.97 -2.29 -0.81 p-value 0.0001 0.022 0.417 Table 5. Change in male premature ejaculation Profile Score in different groups First group Second group Mean difference SE p-value Tramadol paroxetine 2.69 0.72 0.0001 Diff-PEP placebo 4.17 0.80 0.0001 paroxetine placebo 1.48 0.81 0.16 First group 95% Confidence interval Lower bound Upper bound Tramadol 0.97 4.41 Diff-PEP 2.27 6.07 paroxetine -0.44 3.39
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Article|
|Author:||Hamidi-Madani, Ali; Motiee, Reza; Mokhtari, Gholamreza; Nasseh, Hamidreza; Esmaeili, Samaneh; Kazemn|
|Publication:||Journal of Reproduction and Infertility|
|Date:||Jan 1, 2018|
|Previous Article:||CFTR Mutation Analysis in Western Iran: Identification of Two Novel Mutations.|
|Next Article:||Empty Follicle Syndrome Following GnRHa Trigger in PCOS Patients Undergoing IVF Cycles.|
Dosage and administration